Insulin-associated weight gain in diabetes -causes, effects and coping strategies

Diabetes, Obesity and Metabolism

Volumn 9, Issue 6, 2007, Pages 799-812

  Russell Jones, David ^a   Khan, Rehman ^b  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b BASILDON HOSPITAL   (United Kingdom)

Author keywords

Insulin analogues; Insulin associated weight gain; Type 1 diabetes; Type 2 diabetes

Indexed keywords

CHLORPROPAMIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; METFORMIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARCUATE NUCLEUS; BODY MASS; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MECHANISM; DRUG WITHDRAWAL; EXERCISE; FATTY ACID METABOLISM; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LOW CALORY DIET; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 35048841093     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00686.x     Document Type: Review

References (108)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
3. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J 2000; 321: 405-412.
4. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16: 21-31.
5. Betts P, Mulligan J, Ward P, Smith B, Wilkin T. Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). Diabet Med 2005; 22: 144-151.
6. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140-146.
7. DCCT Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24: 1711-1721.
8. DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988; 11: 567-573.
9. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: From promotion to alleviation of obesity. Treat Endocrinol 2003; 2: 33-47.
10. Laville M, Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabetes Metab 2000; 26(Suppl. 3): 42-45.
11. Renner R. New trend in type 2 diabetes moves toward short-term insulins! Better metabolic control, less weight gain. MMW Fortschr Med 2000; 25: 142: 30-32.
12. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18-S24.
13. Snoek FJ. Breaking the barriers to optimal glycaemic control -what physicians need to know from patients' perspectives. Int J Clin Pract Suppl 2002; 129: 80-84.
14. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care 1994; 17: 1178-1185.
15. Bryden KS, Neil A, Mayou RA, Peveler RC, Fairburn CG, Dunger DB. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care 1999; 22: 1956-1960.
16. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV, Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139: 804-812.
17. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
18. Brancati FL, Wang NY, Mead LA, Liang KY, Klag MJ. Body weight patterns from 20 to 49 years of age and subsequent risk for diabetes mellitus: the Johns Hopkins Precursors Study. Arch Intern Med 1999; 159: 957-963.
19. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999; 22: 1266-1272.
20. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: Review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331-339.
21. Markovic TP, Campbell LV, Balasubramanian S et al. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care 1998; 21: 695-700.
22. Khan MA, St Peter JV, Breen GA, Hartley GG, Vessey JT. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes Res 2000; 8: 43-48.
23. Lean ME, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-233.
24. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504.
25. Yki-Jarvinen H, Ryysy L, Kauppila M et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 4037-4043.
26. Escalante-Pulido M, Escalante-Herrera A, Milke-Najar ME, Alpizar-Salazar M. Effects of weight loss on insulin secretion and in vivo insulin sensitivity in obese diabetic and non-diabetic subjects. Diabetes Nutr Metab 2003; 16: 277-283.
27. Haffner SM, D'Agostino R Jr, Mykkanen L et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-568.
28. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003; 5(Suppl. 1): S19-S27.
29. Leong KS, Wilding JP. Obesity and diabetes. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 221-237.
30. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: Role of metabolic and genetic abnormalities. Am J Med 2002; 113(Suppl. 6A): 3S-11S.
31. Purnell JQ, Dev RK, Steffes MW et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003; 52: 2623-2629.
32. Wilkin TJ. The accelerator hypothesis: Weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001; 44: 914-922.
33. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993; 42: 1700-1707.
34. Umpleby AM, Boroujerdi MA, Brown PM, Carson ER, Sonksen PH. The effect of metabolic control on leucine metabolism in type 1 (insulin-dependent) diabetic patients. Diabetologia 1986; 29: 131-141.
35. Russell-Jones DL, Umpleby M. Protein anabolic action of insulin, growth hormone and insulin-like growth factor I. Eur J Endocrinol 1996; 135: 631-642.
36. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
37. De Leeuw I, Vague P, Selam JL et al. Insulin detemir-based used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
38. Gordon D, Wilson M, Paterson KR, Semple CG. Audit of multiple insulin injection regimens in a large outpatient diabetic population. Diabetes Res Clin Pract 1992; 17: 145-150.
39. Malabu UH, McCarthy HD, McKibbin PE, Williams G. Peripheral insulin administration attenuates the increase in neuropeptide Y concentrations in the hypothalamic arcuate nucleus of fasted rats. Peptides 1992; 13: 1097-1102.
40. Orosco M, Rouch C, Gerozissis K. Activation of hypothalamic insulin by serotonin is the primary event of the insulin-serotonin interaction involved in the control of feeding. Brain Res 2000; 872: 64-70.
41. Orosco M, Gerozissis K. Macronutrient-induced cascade of events leading to parallel changes in hypothalamic serotonin and insulin. Neurosci Biobehav Rev 2001; 25: 167-174.
42. Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004; 490: 5-12.
43. Schwartz MW, Niswender KD. Adiposity signaling and biological defense against weight gain: Absence of protection or central hormone resistance? J Clin Endocrinol Metab 2004; 89: 5889-5897.
44. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science 2005; 307: 375-379.
45. Porte D Jr, Baskin DG, Schwartz MW. Insulin signaling in the central nervous system: A critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005; 54: 1264-1276.
46. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002; 16: 475-492.
47. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4: 673-682.
48. Chen JW, Christiansen JS, Lauritzen T. Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab 2003; 5: 223-233.
49. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
50. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am 1997; 26: 599-610.
51. Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Horm Res 1993; 40: 68-79.
52. Russell-Jones DL, Rattray M, Wilson VJ, Jones RH, Sonksen PH, Thomas CR. Intraperitoneal insulin is more potent than subcutaneous insulin at restoring hepatic insulin-like growth factor-I mRNA levels in the diabetic rat: A functional role for the portal vascular link. J Mol Endocrinol 1992; 9: 257-263.
53. Griffen SC, Russell SM, Katz LS, Nicoll CS. Insulin exerts metabolic and growth-promoting effects by a direct action on the liver in vivo: clarification of the functional significance of the portal vascular link between the beta cells of the pancreatic islets and the liver. Proc Natl Acad Sci USA 1987; 84: 7300-7304.
54. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia 1996; 39: 1498-1504.
55. Reaven GM. Beneficial effect of moderate weight loss in older patients with non-insulin-dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc 1985; 33: 93-95.
56. Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: Results of a feasibility study. Diabet Med 2005; 22: 316-322.
57. Curioni CC, Lourenco PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005; 29: 1168-1174.
58. Spiegelman BM. Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 1997; 28: 457-464.
59. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: Is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 2003; 27: 147-161.
60. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006; 29: 510-514.
61. Scarpello JH. Improving survival with metformin: The evidence base today. Diabetes Metab 2003; 29: 6S36-6S43.
62. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: The experimental evidence. Diabetes Metab 2003; 29: 6S71-6S76.
63. Johnson M, Krosnick A, Carson P, McDade AM, Laraway K. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther 1998; 20: 691-698.
64. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ, the Metformin Trial Group. Continuing metformin when starting insulin in patients with Type 2 diabetes: A double-blind randomized placebo-controlled trial. Diabet Med 2005; 22: 634-640.
65. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6: 47-53.
66. Mannucci E, Ognibene A, Cremasco F et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-494.
67. Yasuda N, Inoue T, Nagakura T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002; 15: 779-784.
68. Lindsay JR, Duffy NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005; 22: 654-657.
69. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002; 359: 824-830.
70. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430-441.
71. Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
72. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
73. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
74. Hollander P, Ratner R, Fineman M et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 2003; 5: 408-414.
75. Hollander P, Maggs DG, Ruggles JA et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12: 661-668.
76. Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabet Med 2004; 21: 1204-1212.
77. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: A randomized controlled trial. Diabetes Care 2003; 26: 138-143.
78. Ratner R, Whitehouse F, Fineman MS et al. Adjunctive therapy with pramlintide lowers HbA 1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes 2005; 113: 199-204.
79. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat. Diabetes Metab 2002; 28: 437-445.
80. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: A multicenter study. Obes Res 1996; 4: 391-396.
81. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997; 21: 97-102.
82. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
83. Cox SL. Rimonabant hydrochloride: An investigational agent for the management of cardiovascular risk factors. Drugs Today (Barc) 2005; 41: 499-508.
84. Kruszynska YT, Home PD, Hanning I, Alberti KG. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia 1987; 30: 16-21.
85. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988; 37: 736-744.
86. Markovic TP, Furler SM, Jenkins AB et al. Importance of early insulin levels on prandial glycaemic responses and thermogenesis in non-insulin-dependent diabetes mellitus. Diabet Med 1995; 12: 523-530.
87. Bruttomesso D, Pianta A, Mari A et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105.
88. Owens DR, Cozma LS, Luzio SD. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes Nutr Metab 2002; 15(Suppl. 6): 19-27.
89. Crawford LM, Sinha RN, Odell RM, Comi RJ. Efficacy of insulin pump therapy: Mealtime delivery is the key factor. Endocr Pract 2000; 6: 239-243.
90. Bruttomesso D, Pianta A, Crazzolara D et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: Efficacy, acceptability and quality of life. Diabet Med 2002; 19: 628-634.
91. Kulenovic I, Rasic S, Grujic M. Metabolic control and body mass index in patients with type 1 diabetes on different insulin regimens. Bosn J Basic Med Sci 2004; 4: 23-28.
92. Pinget M, Jeandidier N. Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps. Horm Metab Res 1998; 30: 475-486.
93. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
94. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498-1504.
95. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
96. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.
97. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
98. Hermansen K, Derezinski T, Kim H, Gall M-A. Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes. Diabetologia 2004; 47(Suppl. 1): A273.
99. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
100. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6: 579-588.
101. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: Morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005; 22: 850-857.
102. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
103. Hermansen K, Tamer S. The advantage of less weight gain increases with baseline obesity when insulin detemir rather than NPH Insulin is added to oral agents in type 2 diabetes. Diabetes 2005; 54(Suppl. 1): A67.
104. Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48: 420-426.
105. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.
106. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312: 725-731.
107. Markussen J, Havelund S, Kurtzhals P et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281-288.
108. Hennige AM, Metzinger E, Fritsche A, Häring H-A. Tissue selectivity of insulin detemir action. Diabetes 2005; 54(Suppl. 1): A336.